Metadona – demistificarea unui vechi analgezic

 Methadone – demystifying an old pain killer

First published: 16 mai 2019

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/OnHe.47.2.2019.2324


Methadone is a µ-opioid receptor agonist and NMDA recep­tor antagonist which is often indicated for the management of severe refractory cancer or non-cancer pain, as well as for opioid addiction. This two-part article provides an overview of methadone use in pain management, and its use in opioid addiction will not be covered here. Metha­done has several advantages over other opioids. These ad­van­ta­ges include extended analgesic activity, multiple routes of administration, longer bioavailability, lack of ac­tive metabolites, predominantly intestinal excretion, and its relatively low cost compared to other opioids. This makes methadone an appealing option for patients with impaired creatinine clearance and for those facing finan­cial constraints in obtaining medications. On the other hand, there are notable concerns with this medication that make its use more complex than of other opioids. Metha­done has a variable individual plasma half-life that can lead to ac­cu­mu­lation and toxicity, and extensively utilizes cyto­chrome CYP450, therefore its metabolism can be affected when used in conjunction with inducers and especially in­hi­bi­tors of this cytochrome system. Methadone has also variable and quite complicated conversion formulas when transitioning from other opioids. Additionally, there is a risk for abuse that can lead to accidental overdose or even death. Finally, metha­done can cause QT interval pro­lon­ga­tion that may result in dangerous cardiac arrhythmias such as torsades de points and ventricular tachyarrhythmia. Des­pite its mul­­ti­­ple advantages in pain control, cautionary mes­sages from the European Association for Palliative Care (EAPC) and Na­­tio­­nal Comprehensive Cancer Network (NCCN) ad­vise for use of methadone only by experienced clinicians. It is highly re­­com­­mended that patients are counseled exten­sively on me­tha­­done safety use due to its numerous risks.

administration, conversion, cytochrome CYP450, indications, methadone, opioid, pain manage­ment, safety, WHO analgesic ladder


Metadona este o substanţă opioidă cu activitate agonistică pe receptorii µ şi antagonistică pe receptorii NMDA, fiind in­di­cată atât pentru durerea din cancer, cât şi pentru du­re­rea necanceroasă. Metadona este, de asemenea, in­di­cată şi pentru tratamentul adicţiei la opioide, însă su­biectul nu va fi abordat în acest articol. Avantajele utilizării me­ta­donei în comparaţie cu alte opioide sunt multiple, cele mai cunoscute fiind: acti­vi­ta­te antialgică prelungită; multiple căi de administrare; bio­dis­po­nibilitate mai îndelungată; posibilitatea utilizării la pacienţii cu probleme renale da­to­­ri­tă eliminării preponderent intestinale; lipsa de me­ta­bo­liţi activi; costul scăzut. Pe de altă parte, metadona tre­buie utilizată cu precauţie, din următoarele motive: timp de înjumătăţire care variază de la un pacient la altul; me­­ta­bo­lism hepatic care poate fi influenţat prin utilizarea con­co­mi­ten­tă a metadonei cu substanţe care funcţionează ca inhibitori sau stimulanţi ai sistemului de citocromi CYP450; formule de conversie de la alte opioide care pot fi destul de complicate; risc de abuz, care poate duce la moar­te accidentală; prelungirea intervalului QT, care poate cauza aritmii cardiace, cum ar fi torsades de points şi tahiaritmia ventriculară. The European Association for Palliative Care (EAPC) şi National Comprehensive Cancer Network (NCCN) recomandă ca metadona să fie utilizată de către clinicieni cu experienţă, pentru a asigura bunăstarea şi siguranţa pacientului.

The second part of this article will focus on the most commonly encountered side effects of methadone, including effects on the gastrointestinal, genito-urinary, central nervous, dermatologic, hematologic, respiratory, and cardiovascular systems.

1. Gastrointestinal: nausea, vomiting, bloating, and opioid-induced constipation (OIC) are common side effects seen with all opioids. However, literature suggests methadone carries some advantage over morphine, requiring ten times less laxatives and two times less antiemetics(10).

The European Society for Medical Oncology (ESMO) guide­lines recommend metoclopramide and other antidopaminergic drugs for the treatment of opioid-related nausea and vomiting(17). A review of OIC was published in the February 2018 edition of the journal(18).

A less known and studied entity is the narcotic bowel syndrome (NBS), defined as chronic and recurrent abdominal pain that worsens with continued or escalating doses of opioids, in conjunction with the following criteria:

The pain worsens or incompletely resolves with persistent or increasing doses of opioids.

The pain worsens when the opioid dose wanes and improves when opioids are reinstituted (soar and crash).

Progressive increase in the frequency, duration and intensity of the pain episodes.

The nature and intensity of the pain cannot be explained by other gastrointestinal problems(19).

2. Genito-urinary: urinary hesitancy or retention, amenorrhea, and decreased libido and potency are also seen with opioids. The latter side effects are most likely the result of the opioid-induced hypogonadism (OIH), initially reported in 1970 in male heroin and methadone users who were found to have low testosterone levels. OIH has a prevalence of anywhere between 21% and 86% and seems to occur more frequently in men or in patients on high-dose opioids, especially by intrathecal route(20,21).

Opioids are known to disrupt the secretion of gonadotropin-releasing hormone, resulting in decreased release of luteinizing hormone and follicle stimulating hormone from the pituitary gland, which in turn leads to diminished production of the testosterone or estradiol in the gonads. Another possible mechanism for OIH is opioid-related hyperprolactinemia that leads to decreased production and release of gonadotropin-releasing hormone. The workup should include testing for serum prolactin, estradiol, gonadotropin, testosterone, free testosterone, dehydroepiandrosterone (DHEA), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels, along with bone density. The management of OIH involves reducing the dose of opioids, substituting with other antalgics or hormone replacement therapy with testosterone in men, and estrogen with or without progesterone in women(20,21).

3. Central nervous system (CNS): lightheadedness, drowsiness, sedation, and opioid-induced neurotoxicity (OIN). The last one is represented by cognitive impairment, confusion, hallucinations, myoclonus, seizures, hyperalgesia, and allodynia.

A panel of American and Canadian hospice and palliative care experts recommend intense monitoring for sedation for at least 5 to 7 days after initiating methadone, due to its variable time to steady state concentrations. This observation period could be increased to 10-14 days in elderly patients or those with multiple comorbidities(12).

OIN is a multifactorial syndrome that tends to develop days after initiating an opioid, particularly an opioid with active metabolites, with concomitant use of psychoactive medications (e.g., benzodiazepines, tricyclic antidepressants), or in frail patients with comorbid conditions such as renal failure, preexisting delirium, or severe infections. Methadone is less likely to cause OIN compared to other opioids because it has inactive metabolites, making it well tolerated in renal insufficiency.

There is little evidence for the use of psychostimulants like methylphenidate or modafinil in the management of opioid-induced sedation, and ESMO recommends using these medications only after other methods have been tried and failed(5,22).

4. Dermatologic: diaphoresis and pruritus. Pruritus can be addressed by opioid rotation or use of antihistamines and 5-HT3 (serotonin) antagonists(3).

5. Hematologic: reversible thrombocytopenia has been noted in opioid addicts with chronic hepatitis(13).

6. Respiratory: pulmonary edema and respiratory depression. All opioids can cause respiratory depression, although methadone requires additional caution because its peak respiratory depressant effect occurs later and persists longer than its peak analgesic effect. Consequently, there is higher risk of respiratory depression with very rapid dose escalations during treatment initiation or dose titration, for which reason methadone should not be adjusted sooner than 3-5 days at minimum. Special precautions need to be taken when prescribing methadone in patients suffering from asthma, chronic obstructive pulmonary disease, or any condition causing hypoxia or hypercapnia, where even standard therapeutic doses of methadone may decrease respiratory drive to the point of apnea. It is recommended to use the lowest effective dose of methadone or to try other analgesics including non-opioids for these patients. It is strongly recommended to rapidly use µ-opioid receptor antagonists (e.g., naloxone) if respiratory depression is suspected(3,13,17).

7. Cardiovascular: hypotension, palpitations, arrhythmias, bradycardia or tachycardia, cardiomyopathy, heart failure, acquired QT interval prolongation, torsade de pointes (TdP), ventricular fibrillation and ventricular tachycardia are all potential risks of methadone use.

The QT interval represents the ventricular repolarization on an electrocardiogram (ECG), but because it tends to vary with the heart rate, it is advisable to get the corrected QT interval (QTc) adjusted for the heart rate. The Bazzett’s formula is one of the most used to calculate the QTc:

QTc = QT interval ÷ √RR interval

The guidelines of the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have defined QTc prolongation as an interval longer than 450 ms in males and 470 ms in females. QTc intervals over 500 ms are considered significantly prolonged and associated with an increased risk for TdP(23,24).

QTc prolongation occurs quite frequently in percentages anywhere between 18% and 52%. QTc interval prolongation, with its major complication represented by TdP, is associated with increased risk of cardiovascular mortality. Literature mentions that the risk for a cardiac event is increased by approximately 6% for each 10 ms increase in the QTc(26).

The most common risk factors for QTc prolongation are:

  • Age > 65 years old.

  • Female gender.

  • Genetic predisposition, such as:

    • congenital long QT syndrome (LQTS)

    • family history of sudden death at age younger than 50 years old

    • genetic inherited arrhythmias (e.g., Brugada syndrome)

    • history of previously drug-induced QT prolongation.

  • Structural heart disease or cardiac abnormalities:

    • left ventricular failure

    • history of myocardial infarction

    • cardiomyopathy etc.

  • Bradycardia.

  • Electrolyte abnormalities: hypokalemia, hypomagnesemia, hypocalcemia.

  • Nutritional deficits: eating disorders, extreme diets.

  • Comorbidities:

    • sepsis

    • kidney disease that could cause inadequate elimination of QT prolonging drugs

    • hepatic disease that could affect the metabolism of the QT prolonging drugs via CYP450 cytochrome system

    • neurological events: hemorrhage, stroke etc.

    • diabetes mellitus.

  • Other: fast intravenous infusion that could lead to rapid accumulation of QT prolonging drugs

  • Polypharmacy: concomitant administration of several QT prolonging agents represents the main culprit for QTc prolongation(24-32). The most frequently encountered medications that could cause QTc prolongation are included in Table 4.

Table 4. Most commonly used medications that could prolong the QTc interval(23-32)
Table 4. Most commonly used medications that could prolong the QTc interval(23-32)

Patients with cancer are at increased risk of developing QTc prolongation. They may have poor oral intake with persistent nausea and vomiting, particularly during chemotherapy, or diarrhea that may expose them to various electrolyte imbalances. Additionally, they often have multiple comorbidities and are frequently exposed to multiple drugs with QT prolonging activity, such as chemotherapy agents, antiemetics, antidepressants, diuretics and antibiotics(28). It is estimated that methadone prolongs the QTc interval by blocking hERG (human Ether-à-go-go-Related Gene) potassium channel, which causes an inhibition of the outward potassium current during myocardial repolarization, leading to a prolonged repolarization time. The risk for QTc prolongation seems to be higher with i.v. methadone compared to oral formulations, possibly related to the preservative chlorobutanol in the i.v. preparation, which has been shown to independently prolong the QTc interval(3,25).

Careful examination of the patient’s family and medical history and medication list for a potential drug to drug interaction at CYP450 cytochrome level needs to be employed prior to initiating methadone. Dose reduction is recommended when using methadone concurrently with other QT interval prolonging medications or medications that act as CYP450 cytochrome inhibitors and result in decreased methadone metabolism. Table 1 in the first part of this article presents the frequently encountered CYP450 cytochromes inhibitors and inducers.

Various panels of experts proposed the recommendations listed below when prescribing methadone for pain or addiction to patients seeking curative, life-prolonging measures:

A. Inform patients of methadone side effects, particularly arrhythmia. Patients should be counseled to immediately seek medical assistance if experiencing syncope, fainting, palpitations, or dizzy spells after initiating methadone.

B. Review the patient’s family and medical history and medication list to look for possible interactions between methadone and other drugs that possess QTc interval prolonging properties or could slow the elimination of methadone.

C. Obtain a baseline ECG before initiating methadone, particularly in patients with positive risk factors, prior ECG with QTc>450 ms, or prior history of cardiac arrhythmia.

D. Do not initiate methadone if screening ECG shows a QTc interval >500 ms.

E. Get a follow-up ECG. There are discrepancies regarding the timing for the follow-up ECG. Some authors recommend repeating the ECG 24 hours after initiating therapy with methadone and four days after achieving a steady state. Others recommend repeating the ECG after the patient is at a stable dose of methadone for one week, or one week after increasing the methadone. Finally, other articles mention repeating the ECG in 2-4 weeks.

F. Obtain additional ECGs when the total daily dose of methadone exceeds 40, 60, or 100 mg (opinions differ), when new risk factors for QTc prolongation are detected, when proarrhythmic drugs are added, or if the patient has unexplained syncope or seizures.

G. Discuss the risks and benefits of methadone therapy if the QTc is greater than 450 ms but less than 500 ms, and consider decreasing the dose of methadone or eliminating other drugs that could prolong QTc interval. Monitor more frequently.

H. Taper the methadone or consider an opioid rotation and eliminate other QTc prolonging medications if QTc interval is greater than 500 ms.

I. Keep in mind that each 10 ms increase in QTc exponentially increases the risk for TdP and discontinue medications with QTc prolonging properties if the QTc interval increases by more than 60 ms after addition of such drugs(3,11,12,25,28,33).

All these recommendations, particularly ECG monitoring, are not indicated in patients enrolled in hospice services or at the end of life, where adequate and aggressive pain and symptom management are of paramount importance.

8. Potential for misuse and abuse. The National Comprehensive Cancer Network (NCCN) defines misuse as an intentional or unintentional inappropriate use of a prescription drug regardless of the motivation (such as impairment). The same organization defines abuse as a maladaptive pattern of use of a prescription medication, leading to significant clinical impairment and/or distress(15).

Methadone, like all µ-opioid receptor agonists, can be abused and plays an unfortunate role in the so-called opioid epidemic that has become a serious national crisis affecting the American public health and social and economic welfare. Abuse of methadone poses a risk of overdose and death, risk which is significantly increased by concomitant use or abuse of other CNS depressants.

Data from the Center for Disease Control and Prevention shows that the number of deaths involving methadone jumped by 468% from 1999 to 2005, with close to 80% of these deaths being unintentional(34). However, after 2006, deaths from methadone-involved overdose declined by about 6.5% per year, whereas diversion started to decline by an average of 12.8% per year starting from 2010. Methadone claimed an unfortunate toll of 3,287 lives in 2017(35). Data related to opioid overdose deaths are summarized in Figure 2.

Figure 2. Opioid overdose death rates
Figure 2. Opioid overdose death rates

In conclusion, methadone is an excellent pain killer, relatively inexpensive, favored in renal insufficiency due to its intestinal elimination and lack of active metabolites, as well as for refractory pain especially with a neuropathic component. However, it requires manipulation by expert hands due to its extensive metabolism via CYP450 cytochrome system and its numerous possible side effects, thus requiring close monitoring, especially at the time of initiation or up titration.  

Conflict of interests: The authors declare no conflict of interests.

Abbreviation list: CNS: Central Nervous System; DHEA: Dehydroepiandrosterone; EAPC: European Association for Palliative Care; ECG: Electrocardiogram; ESMO: European Society for Medical Oncology; FDA: Food and Drug Administration; FSH: Follicle Stimulating Hormone; hERG: human Ether-à-go-go-Related Gene; i.v.: Intravenous; LH: Luteinizing Hormone; OIC: Opioid-Induced Constipation; OIH: Opioid-Induced Hypogonadism; OIN: Opioid-Induced Neurotoxicity; NBS: Narcotic Bowel Syndrome; QTc: Corrected QT; TCA: Tricyclic antidepressants; TdP: Torsade de Pointes


  1. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012 Feb; 13(2):e58-68. DOI: 10.1016/S1470-2045(12)70040-2.
  2. Namukwaya E, Leng M, Downing J, Katabira E. Cancer Pain Management in Resource-Limited Settings: A Practice Review. Pain Research and Treatment. 2011; vol. 2011: 393404, doi: 10.1155/2011/393404, PMCID: PMC3236429, PMID: 22191020
  3. Shaiova L, Berger A, Blinderman CD, Bruera E, Davis MP, Derby S, Inturrisi C, Kalman J, Mehta D, Pappagallo M, Perlov E. Consensus guideline on parenteral methadone use in pain and palliative care. Palliative and Supportive Care. 2008 Jun; 6(2):165-76. DOI: 10.1017/S1478951508000254.
  4. WHO Model List of Essential Medicines, 20th List, March 2017. Available at:
  5. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. Journal of Palliative Medicine. 2004 July; Vol. 5, No. 1, PMID: 11839235, DOI:10.1089/10966210252785097
  6. Dinis-Oliveira RJ. Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response. Drug Metabolism Reviews. 2016; vol.48, Issue 4, 568-576, DOI: 10.1080/03602532.2016.1192642
  7. Fonseca F, de la Torre R, Díaz L, Pastor A, Cuyàs E, Pizarro N, Khymenets O, Farré M, Torrens. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLOS One. 2011 May 12; 6(5):e19527. DOI: 10.1371/journal.pone.0019527.
  8. US Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: website.
  9. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. American Journal of Addiction. 2010; 19(1):4-16. PMID: 20132117.
  10. Leppert W. The role of methadone in cancer pain treatment – a review. Interna­tio­nal Journal of Clinical Practice, 2009 Jul; 63(7):1095-109. DOI: 10.1111/j.1742-1241.2008.01990.x
  11. Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, Inturrisi C, Knight JR, Otis-Green S, Marcus S, Mehta D, Meyer MC, Portenoy R, Savage S, Strain E, Walsh S, Zeltzer L. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. The Journal of Pain. 2014 Apr; 15(4):321-37. DOI: 10.1016/j.jpain.2014.01.494
  12. McPherson ML, Walker KA, Davis MP, Bruera E, Reddy A, Paice J, Malotte K, Lockman DK, Wellman C, Salpeter S, Bemben NM, Ray JB, Lapointe BJ, Chou R. Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. Journal of Pain and Symptom Management. 2018 Dec 19; pii: S0885-3924(18)31114-X. 
  13. Methadone package insert. Available at:
  14. Pollock AB, Tegeler ML, Morgan V, Baumrucker SJ. Morphine to methadone conversion: an interpretation of published data. American Journal of  Hospice and Palliative Care. 2011 Mar; 28(2):135-40. DOI: 10.1177/1049909110373508. 
  15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Adult Cancer Pain, Version 1.2018,
  16. Plonk WM. Simplified methadone conversion. Journal of Palliative Medicine. 2005 Jun; 8(3):478-9.PMID:16021683.
  17. Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI; on behalf of the ESMO Guidelines Committee, Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018; 29 (Supplement 4): iv166–iv191, PMID: 30052758, DOI:10.1093/annonc/mdy152.
  18. Buga S, Banerjee C, Patel P, Zachariah F, Mooney S. Opioid-induced constipation. 2018; Anul XII, Nr. 43 (2), DOI: 10.26416/OnHe.43.2.2018
  19. Grunkemeier DMS, Cassara JE, Dalton CB, Drossman DA. The Narcotic Bowel Syndrome: clinical features, pathophysiology and management. Clinical Gastroenterology and Hepatology. 2007 Oct; 5(10): 1126–1122, PMID: 17916540, DOI:10.1016/j.cgh.2007.06.013.
  20. Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid-induced hypogonadism. British Medical Journal. 2010; 341: c4462,  PMID: 20807731, DOI: 10.1136/bmj.c4462
  21. Colameco S, Coren JS. Opioid-induced endocrinopathy. The Journal of the American Osteopathic Association. 2009 Jan; Vol. 109, 20-25, PMID:19193821.
  22. Gallagher R. Opioid-induced neurotoxicity. Canadian Family Physician. 2007 Mar; 53(3): 6–427, PMID: 17872676.
  23. Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. International Journal of Clinical Pharmacy. 2017 Feb; 39(1):16-25, PMID: 28012118, DOI:10.1007/s11096-016-0414-2.
  24. Khan Q, Ismail M, Haider I, Ali Z. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients. Journal of the Formosan Medical Association. 2019 Jan; 118(1 Pt 1):109-115, PMID: 29458991, DOI: 10.1016/j.jfma.2018.01.016.
  25. van den Beuken-van Everdingen MHJ, Geurts JW, Patijn J. Prolonged QT interval by methadone: Relevance for daily practice? A prospective study in patients with cancer and noncancer pain. Journal of Opioid Management. 2013 Jul-Aug; 9(4):263-7, PMID: 24353019, DOI:10.5055/jom.2013.0167.
  26. Tomaselli Muensterman E, Tisdale JE. Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review. Pharmacotherapy. 2018 Aug; 38(8):813-821, PMID: 29882591, DOI: 10.1002/phar.2146.
  27. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiology and Drug Safety. 2005 Nov; 14(11):747-53, DOI: 10.1002/pds.1112.
  28. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017 Dec 7; 6(12), PMID: 29217664, DOI:10.1161/JAHA.117.007724.
  29. Heemskerk CPM, Pereboom M, van Stralen K, Berger FA, van den Bemt PMLA, Kuijper AFM, van der Hoeven RTM, Mantel-Teeuwisse AK, Becker ML. Risk factors for QTc interval prolongation. European Journal of Clinical Pharmacology. 2018 Feb; 74(2):183-191, PMID: 29167918, DOI: 10.1007/s00228-017-2381-5.
  30. Khan Q, Ismail M, Khan S. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacology and Toxicology. 2017; 18:75, PMID: 29191244, DOI: 10.1186/s40360-017-0181-2.
  31. Franchi C, Ardoino I, Rossio R, Nobili A, Biganzoli EM, Marengoni A, Marcucci M, Pasina L, Tettamanti M, Corrao S, Mannucci PM, REPOSI Investigators. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. Drugs and Aging. 2016 Jan; 33(1):53-61, PMID: 26693921, DOI:10.1007/s40266-015-0337-y.
  32. Isbister GK. Risk assessment of drug-induced QT prolongation. Australian Prescriber. 2015 Feb; 38(1): 20–24, PMID: 26648606, DOI: 10.18773/austprescr.2015.003.
  33. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MCP. QTc Interval Screening in Methadone Treatment. Annals of Internal Medicine. 2009 Mar 17; 150(6):387-95, PMID: 19153406.
  34. Fingerhut LA. Increases in Poisoning and Methadone-Related Deaths: United States, 1999-2005. Available at:
  35. Jones CM, Baldwin GT, Manocchio T, White JO, Mack KA. Trends in Methadone Distribution for Pain Treatment, Methadone Diversion, and Overdose Deaths, United States, 2002–2014. Available at:
  36. Wood E. Strategies for Reducing Opioid-Overdose Deaths - Lessons from Canada. New England Journal of Medicine. 2018 Apr 26; 378(17):1565-1567, PMID: 29694813, DOI: 10.1056/NEJMp1800216.

Articole din ediţiile anterioare

PALLIATIVE CARE | Ediţia 1 46 / 2019

Metadona – demistificarea unui vechi analgezic

Sorin Buga, Stefanie Mooney, Purvi Patel, Heather Bitar, Linda Hillebrand, Samina Qamar, Finly Zachariah, Chandana Banerjee

Metadona este o substanţă opioidă cu activitate agonistică pe receptorii µ şi antagonistică pe receptorii NMDA, fiind indicată atât pentru durerea ...

27 martie 2019
PALLIATIVE CARE | Ediţia 3 56 / 2021

Prurit, scărpinat, prurit – pruritul indus de opioide

Sorin Buga, Andrada Totoran

Opioidele sunt medicamente esenţiale în tratarea durerii din cancer.

25 octombrie 2021
CASE PRESENTATION | Ediţia 3 / 2016

Ambivalenţa chimică: prezentare de caz

Sorin Buga, Chandana Banerjee, Finly Zachariah, Bonnie Freeman

Ambivalenţa chimică este un răspuns maladaptativ întâlnit la pacienţii trataţi cu opioide care ajung să utilizeze această medicaţie nu neapărat pen...

07 martie 2017
REVIEW | Ediţia 2 43 / 2018

Constipaţia indusă de opioide

Sorin Buga, Chandana Banerjee, Purvi Patel, Finly Zachariah, Stefanie Mooney

Opioidele, prescrise de medicii oncologi şi de cei de în­gri­ji­re paliativă pentru uşurarea durerii din cancer, au efecte se­cun­dare multiple, co...

16 mai 2018